Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24221619 | 0.83 | GRM5 (0.32) | GRM5 | |
| SCHEMBL22993267 | 0.74 | CYP2C19 (0.43) | TSHR | |
| SCHEMBL21730188 | 0.73 | MAPT (0.36) | GRM5 | |
| SCHEMBL24253486 | 0.71 | MAOA (0.40) | — | |
| SCHEMBL22723932 | 0.70 | CYP3A4 (0.37) | GRM5TSHR | |
| SCHEMBL24783744 | 0.69 | MAPK8 (0.41) | NOTUM | |
| SCHEMBL19864622 | 0.68 | JAK2 (0.34) | GRM5NOTUMTSHRMAPK1 | |
| SCHEMBL22694924 | 0.68 | GRM5 (0.30) | GRM5 | |
| SCHEMBL22387665 | 0.67 | ADRA2A (0.37) | TSHRMAPK1 | |
| SCHEMBL11639939 | 0.67 | ADRA2A (0.40) | TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055948-A1 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | BACE1, BACE2, GSAP | GRM5 1380/4885NOTUM 1209/4885TSHR 3220/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | GRM5 1995/4885NOTUM 2800/4885TSHR 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.